about
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraRisk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.Activity of BKM120 and BEZ235 against Lymphoma Cells.Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.Genomic profiling of enzastaurin-treated B cell lymphoma RL cells.Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasDialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphyet alIntroduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patientsIncidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern ItalyRational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma
P50
Q30966717-3D853ED1-183C-4A42-B984-82AB480F1FABQ33436585-47954B15-B990-43D4-BA59-5BCB449AE634Q33558130-7D011C35-7439-4479-B8B1-8873DC23B361Q36441553-73210D67-4C73-4701-B4DA-2A47DBEE2E66Q38198754-0E0BB61E-9D3B-489A-A542-4040F5524C77Q38940707-F04DF20A-679E-406A-97CE-B24D4A82C4BAQ39740601-8C2C65ED-BCF4-4964-A2E3-D66A50CEDF0CQ40095723-24E7BE1A-FF51-430A-B90C-3E5F6B4F8317Q40979223-1C04C9FC-DA7D-4FE8-B0A6-15791A471240Q41148150-E6183D09-E9DE-4255-8212-8AA2F8E96342Q41573605-AA632C4E-E924-4278-9ADE-A82B194B0835Q41855451-FD561F64-7D3C-4168-90FD-D4290E5577C6Q42399897-3C4CFACA-A44B-47DA-9929-9979F4DB49ACQ43534642-0AD68BBA-93BF-4A04-9071-A823B46722FEQ44939805-A14F6E0B-AC7D-4B42-BAC5-08CDA02EF8ADQ44951134-F46C2A7A-E225-4D24-8B72-08923D1DB90EQ45114730-7337C5E9-10AE-45E2-86F5-42E10F00452EQ46563541-A47AB832-A480-4DDB-899D-A43F1F45D425Q46758819-8D9E6D76-320C-42B0-ABAD-54C3F66A292EQ53080440-86556595-F2F2-48BE-9E4E-7EA5680B328FQ53090405-FDAF796D-7373-41D7-97D3-EA790BDAC830Q53183896-99A93112-77A0-4BBC-A76F-23B7CB3D858DQ54559830-462FB39A-AA35-4190-9FF9-C8ACFC6BA2FAQ60641265-7E6DA2FE-8ECE-49D9-A333-0318F523AD66Q62784611-EE208F22-0062-4DDD-9C13-25FE18F5056EQ62785019-AD216D9D-8426-4CB6-BA79-91988F9968BAQ80678741-D4EA96E2-5D6C-4792-BF35-6EE8D4F510E1Q84439864-EC8C7EF0-D805-43A3-96A3-6F3468510177
P50
description
researcher ORCID ID = 0000-0002-9538-2499
@en
wetenschapper
@nl
name
Alessia Bari
@ast
Alessia Bari
@en
Alessia Bari
@es
Alessia Bari
@nl
type
label
Alessia Bari
@ast
Alessia Bari
@en
Alessia Bari
@es
Alessia Bari
@nl
prefLabel
Alessia Bari
@ast
Alessia Bari
@en
Alessia Bari
@es
Alessia Bari
@nl
P106
P1153
23102143000
P31
P496
0000-0002-9538-2499